<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR183">
 <label>183.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>McDermott</surname>
    <given-names>David F.</given-names>
   </name>
   <name>
    <surname>Sosman</surname>
    <given-names>Jeffrey A.</given-names>
   </name>
   <name>
    <surname>Sznol</surname>
    <given-names>Mario</given-names>
   </name>
   <name>
    <surname>Massard</surname>
    <given-names>Christophe</given-names>
   </name>
   <name>
    <surname>Gordon</surname>
    <given-names>Michael S.</given-names>
   </name>
   <name>
    <surname>Hamid</surname>
    <given-names>Omid</given-names>
   </name>
   <name>
    <surname>Powderly</surname>
    <given-names>John D.</given-names>
   </name>
   <name>
    <surname>Infante</surname>
    <given-names>Jeffrey R.</given-names>
   </name>
   <name>
    <surname>Fassò</surname>
    <given-names>Marcella</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>Yan V.</given-names>
   </name>
   <name>
    <surname>Zou</surname>
    <given-names>Wei</given-names>
   </name>
   <name>
    <surname>Hegde</surname>
    <given-names>Priti S.</given-names>
   </name>
   <name>
    <surname>Fine</surname>
    <given-names>Gregg D.</given-names>
   </name>
   <name>
    <surname>Powles</surname>
    <given-names>Thomas</given-names>
   </name>
  </person-group>
  <article-title>Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study</article-title>
  <source>Journal of Clinical Oncology</source>
  <year>2016</year>
  <volume>34</volume>
  <issue>8</issue>
  <fpage>833</fpage>
  <lpage>842</lpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2015.63.7421</pub-id>
  <?supplied-pmid 26755520?>
  <pub-id pub-id-type="pmid">26755520</pub-id>
 </element-citation>
</ref>
